Vaxcyte’s (PCVX) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Vaxcyte (NASDAQ:PCVX) in a research report report published on Monday morning, MarketBeat.com reports. They currently have a $120.00 target price on the stock.

PCVX has been the subject of several other research reports. BTIG Research restated a “buy” rating and set a $89.00 target price on shares of Vaxcyte in a research note on Monday, October 5th. Wall Street Zen raised Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Bank of America dropped their price target on Vaxcyte from $133.00 to $130.00 and set a “buy” rating on the stock in a research report on Monday, September 28th. Zacks Research upgraded Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Finally, Needham & Company LLC upped their price target on Vaxcyte from $110.00 to $122.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $110.50.

Vaxcyte Stock Performance

PCVX stock opened at $67.55 on Monday. Vaxcyte has a 52-week low of $39.87 and a 52-week high of $90.75. The company has a 50-day moving average of $60.90 and a two-hundred day moving average of $56.95.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same period last year, the company earned ($1.22) earnings per share. Equities analysts anticipate that Vaxcyte will post -7.47 EPS for the current fiscal year.

Insider Transactions at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 10,000 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $53.89, for a total value of $538,900.00. Following the sale, the chief financial officer directly owned 105,176 shares in the company, valued at $5,667,934.64. This trade represents a 8.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jim Wassil sold 18,000 shares of the firm’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $86.74, for a total transaction of $1,561,320.00. Following the completion of the sale, the executive vice president owned 145,435 shares in the company, valued at $12,615,031.90. This represents a 11.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 92,890 shares of company stock worth $6,320,569. 3.30% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Vaxcyte

Several hedge funds have recently made changes to their positions in PCVX. Avior Wealth Management LLC raised its holdings in Vaxcyte by 17.5% in the 3rd quarter. Avior Wealth Management LLC now owns 6,747 shares of the company’s stock valued at $384,000 after acquiring an additional 1,003 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Vaxcyte by 31.3% in the 3rd quarter. GAMMA Investing LLC now owns 1,769 shares of the company’s stock worth $101,000 after acquiring an additional 422 shares during the period. First Light Asset Management LLC lifted its position in shares of Vaxcyte by 143.4% in the 2nd quarter. First Light Asset Management LLC now owns 345,157 shares of the company’s stock worth $20,064,000 after acquiring an additional 203,373 shares during the period. Engineers Gate Manager LP acquired a new stake in shares of Vaxcyte during the 2nd quarter worth approximately $1,906,000. Finally, IFP Advisors Inc grew its holdings in shares of Vaxcyte by 72.8% during the 2nd quarter. IFP Advisors Inc now owns 560 shares of the company’s stock worth $33,000 after purchasing an additional 236 shares in the last quarter. Institutional investors own 96.78% of the company’s stock.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing vaccines to help prevent serious bacterial infections. The company uses its cell-free protein synthesis and advanced conjugation technologies to design vaccines intended to provide broad and durable protection while addressing limitations of existing vaccine products.

Vaxcyte’s lead programs are pneumococcal conjugate vaccine candidates, including VAX-24 and VAX-31, which are designed to target a broad range of pneumococcal serotypes.